Velexbru hydrochloride is currently not explicitly approved for primary central nervous system lymphoma (PCNSL), but as a BTK inhibitor, it may exert potential therapeutic effects through the blood-brain barrier. Existing data shows that PCNSL has significant therapeutic effects on B-cell malignancies, but more clinical evidence is needed to support PCNSL.

Current status of indications

1. Approved indications

The drug is currently approved for recurrent/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and requires prior systemic treatment with BTK inhibitors.

2. Exploratory Application of PCNSL

Although not officially approved, BTK inhibitors have the ability to cross the blood-brain barrier, making them a potential treatment option for PCNSL, and should be used beyond the instructions under the guidance of a doctor.

Mechanism of action and therapeutic basis

3. Targeting the BTK pathway

By irreversibly inhibiting Bruton tyrosine kinase (BTK), blocking B cell receptor signaling, and inhibiting malignant B cell proliferation and survival, this mechanism may also be effective for PCNSL.

4. Blood-brain barrier penetrability

Compared to traditional chemotherapy drugs, BTK inhibitors have better central nervous system permeability, providing pharmacological basis for PCNSL treatment.

clinical evidence

5. Reference for other BTK inhibitors

Ibrutinib, a similar drug, showed an objective response rate of 52% -75% in PCNSL, suggesting that it may have similar potential, but further research is needed to verify its efficacy.

6. Prospects of combination therapy

Existing studies have explored the combination of BTK inhibitors with chemotherapy or immunomodulators, which may improve the survival prognosis of PCNSL patients.